Insider Intelligence delivers leading-edge research to clients in a variety of forms, including full-length reports and data visualizations to equip you with actionable takeaways for better business decisions.
In-depth analysis, benchmarks and shorter spotlights on digital trends.
Learn More
Interactive projections with 10k+ metrics on market trends, & consumer behavior.
Learn More
Proprietary data and over 3,000 third-party sources about the most important topics.
Learn More
Industry KPIs
Industry benchmarks for the most important KPIs in digital marketing, advertising, retail and ecommerce.
Learn More
Client-only email newsletters with analysis and takeaways from the daily news.
Learn More
Analyst Access Program
Exclusive time with the thought leaders who craft our research.
Learn More

About Insider Intelligence

Our goal at Insider Intelligence is to unlock digital opportunities for our clients with the world’s most trusted forecasts, analysis, and benchmarks. Spanning five core coverage areas and dozens of industries, our research on digital transformation is exhaustive.
Our Story
Learn more about our mission and how Insider Intelligence came to be.
Learn More
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Contact Us
Speak to a member of our team to learn more about Insider Intelligence.
Contact Us
See our latest press releases, news articles or download our press kit.
Learn More
Advertising & Sponsorship Opportunities
Reach an engaged audience of decision-makers.
Learn More
Browse our upcoming and past webinars and other events.
Learn More
Tune in to eMarketer's daily, weekly, and monthly podcasts.
Learn More

Biogen, Happify Health team up to move the needle on mental health therapies for MS patients

The news: Biogen is teaming up with digital therapeutics entrant Happify Health on an AI-powered digital solution that supports the mental well-being of multiple sclerosis (MS) patients.

Key details: Happify Health’s digital tool configured for MS (Kopa) gives members access to mental health services, neurology providers, dietitians, and rehabilitation professionals.

  • The tool uses AI to personalize content to patients' life stages and symptoms.
  • MS patients can ask experts questions and also discuss their challenges with MS patients in similar stages.
  • For its part, Biogen will add new educational content and resources to support Happify’s platform.

Happify Health’s pharma streak:

  • In 2019, Happify inked a partnership with Sanofi to develop an app to improve mental health in MS patients.
  • And earlier this month, Happify and Barcelona-based pharma company Almirall launched their DTx solution for psoriasis patients, Claro, in select European countries.
  • With a name like Biogen on its partnership roster, Happify could secure more B2B partnerships. Especially since the biotech giant has years of experience in specializing treatment for neurological diseases.

The bigger picture: Doctors are warming up to DTx. That could be a bright spot for chronic disease patients suffering from anxiety and depression.

  • Most physicians (50%) are “extremely likely” or “somewhat likely” (45%) to prescribe prescription digital therapies to their patients, per a February 2022 Cowen & Company survey of 200 US physicians.
  • That’s because physicians say many DTx solutions like Happify Health and Pear Therapeutics are low-risk (60%) and can augment existing treatment (76%), per Cowen & Company.

Some patients could use DTx tools to manage their mental health conditions without risking major side effects that come with traditional meds. That’s important for health outcomes, because depression is one of the most common symptoms of MS. In fact, risk of suicide in MS patients is twice as high, per Mental Health America.